<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/64BC5E73-972F-41E1-A12C-D97DC9BDFB93"><gtr:id>64BC5E73-972F-41E1-A12C-D97DC9BDFB93</gtr:id><gtr:name>MRC Clinical Sciences Centre</gtr:name><gtr:address><gtr:line1>Faculty of Medicine Imperial College</gtr:line1><gtr:line2>London Hammersmith Campus</gtr:line2><gtr:line3>Du Cane Road</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>W12 0NN</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/64BC5E73-972F-41E1-A12C-D97DC9BDFB93"><gtr:id>64BC5E73-972F-41E1-A12C-D97DC9BDFB93</gtr:id><gtr:name>MRC Clinical Sciences Centre</gtr:name><gtr:address><gtr:line1>Faculty of Medicine Imperial College</gtr:line1><gtr:line2>London Hammersmith Campus</gtr:line2><gtr:line3>Du Cane Road</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>W12 0NN</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/702013CF-3EDB-44D9-867A-2CEB10F9E474"><gtr:id>702013CF-3EDB-44D9-867A-2CEB10F9E474</gtr:id><gtr:firstName>Kishore</gtr:firstName><gtr:surname>Bhakoo</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_U120074337"><gtr:id>2B939714-6E3E-4477-9BD7-14FEF2491EEE</gtr:id><gtr:title>Stem Cell Imaging</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_U120074337</gtr:grantReference><gtr:abstractText>One of the key questions when using Stem Cells to repair tissues is; do the cells get there? Cell therapists need to follow stem cells for weeks, months, and even years after they are introduced as therapy.||This requirement has led us to experiment with agents that will make the stem cells visible after transplantation. Methods used for studying patients using magnetic resonance imaging can be modified to visualize these cells in the patients.||A key technique in optimizing cell therapy is MRI of cells labeled with superparamagnetic iron oxides. With its ability to precisely target cell delivery, track cell migration, and noninvasively evaluate living subjects over time, this technique will help to bridge the gap between bench and bedside.</gtr:abstractText><gtr:technicalSummary>Stem cell research is undergoing a critical transition from being a discipline of the basic sciences to being recognized as a potential component of medical practice. Cell transplants to replace cells lost due to injury or degenerative diseases, for which there are currently no cures, are being pursued in a wide range of experimental models. The monitoring of cellular grafts, non-invasively, is an important aspect of the ongoing efficiency and safety assessment of cell-based therapies. Magnetic resonance imaging methods are potentially well suited for such an application as they produce non-invasive images of opaque tissues. For transplanted stem cells to be visualised and tracked by MRI, they need to be tagged so that they are MR visible. We are developing and implementing a programme of molecular imaging in pre-clinical models that is directed towards improving our understanding of stem cell migration in the context of the whole organism. In order to achieve these goals we are engineering novel MRI contrast agents and developing specific tagging molecules to deliver efficient amounts of contrast agents into stem cells. The intracellular contrast agents are based on either paramagnetic nanoparticles, such as dextran-coated iron oxide, or other MR contrast agents. Methods for monitoring implanted stem cells non-invasively in vivo will greatly facilitate the clinical realization and optimization of the opportunities of stem cell based therapies. The specific aims of the programme are: 1. To engineer polymer-enveloped super-paramagnetic nanoparticles to deliver efficient amounts of MR contrast agents to cells, achieving intracellular retention, efficient relaxivity, high in vivo MR signal-to-noise ratios and tolerable toxicity levels. 2. To develop generic methodologies for the tracking of cells in vivo using magnetic resonance imaging. The following models will be used: Glial progenitors implanted in various animal models: Multiple Sclerosis, Spinal Cord Repair, Developmental Fate Neuronal stem cells implanted in animal models: Parkinsons Disease, Stroke (co-registration between PET and MRI) Track inflammatory cells involved in: Allergic response in lungs, CNS inflammation, host vs Graft rejection Cardiac stem cells and progenitors implanted in ischemic heart - (co-registration between PET and MRI)</gtr:technicalSummary><gtr:fund><gtr:end>2009-04-01</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2004-08-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>1546335</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications/><gtr:identifiers><gtr:identifier type="RCUK">MC_U120074337</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>F3822669-BB5A-4BB4-BAE0-DCB9DE36E092</gtr:id><gtr:percentage>58</gtr:percentage><gtr:text>Generic Health Relevance</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>041997EB-CFD8-493D-B0F8-DFA35451D0BE</gtr:id><gtr:percentage>42</gtr:percentage><gtr:text>Neurological</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>CF950C9A-DB16-4E23-8AEB-94548777BCA1</gtr:id><gtr:percentage>42</gtr:percentage><gtr:text>1.1  Normal biological development and functioning</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>12A0B409-0C29-4056-9092-2D86E44017F3</gtr:id><gtr:percentage>42</gtr:percentage><gtr:text>1.4  Methodologies and measurements</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>13</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>DD81206B-5EB4-4BCC-AEF7-808A64606E0E</gtr:id><gtr:percentage>3</gtr:percentage><gtr:text>5.2  Cellular and gene therapies</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>